These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 26035560)

  • 1. [Effect of a vascular event on drug regimen compliance in patients with coronary atherosclerosis].
    Bunova SS; Usacheva EV; Ivanov AY
    Angiol Sosud Khir; 2015; 21(2):15-9. PubMed ID: 26035560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
    Mehran R; Baber U; Steg PG; Ariti C; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Berger PB; Iakovou I; Dangas G; Waksman R; Antoniucci D; Sartori S; Krucoff MW; Hermiller JB; Shawl F; Gibson CM; Chieffo A; Alu M; Moliterno DJ; Colombo A; Pocock S
    Lancet; 2013 Nov; 382(9906):1714-22. PubMed ID: 24004642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges adhering to a medication regimen following first-time percutaneous coronary intervention: A patient perspective.
    Pettersen TR; Fridlund B; Bendz B; Nordrehaug JE; Rotevatn S; Schjøtt J; Norekvål TM;
    Int J Nurs Stud; 2018 Dec; 88():16-24. PubMed ID: 30165236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet effect of aspirin in patients with coronary artery disease.
    Grove EL
    Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study.
    Montalescot G; Rangé G; Silvain J; Bonnet JL; Boueri Z; Barthélémy O; Cayla G; Belle L; Van Belle E; Cuisset T; Elhadad S; Pouillot C; Henry P; Motreff P; Carrié D; Rousseau H; Aubry P; Monségu J; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Beygui F; Vicaut E; Collet JP;
    Circulation; 2014 May; 129(21):2136-43. PubMed ID: 24718568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease.
    Kumbhani DJ; Fonarow GC; Cannon CP; Hernandez AF; Peterson ED; Peacock WF; Laskey WK; Deedwania P; Grau-Sepulveda M; Schwamm LH; Bhatt DL;
    Am J Med; 2015 Apr; 128(4):426.e1-9. PubMed ID: 25433302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation.
    Bianchi C; Montalvo V; Ou HW; Bishop V; Abou-Zamzam AM
    Ann Vasc Surg; 2007 Mar; 21(2):163-6. PubMed ID: 17349357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uninsured South Florida vascular surgery patients are less likely to receive optimal medical management than their insured counterparts.
    Yeh D; Jones M; Schulman C; Karmacharya J; Velazquez OC
    J Vasc Surg; 2010 Apr; 51(4 Suppl):4S-8S. PubMed ID: 20346337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year outcomes after deployment of XIENCE V everolimus-eluting stents in patients undergoing percutaneous coronary intervention of bifurcation lesions: a report from the SPIRIT V single arm study.
    Džavík V; Kaul U; Guagliumi G; Chevalier B; Smits PC; Stuteville M; Li D; Sudhir K; Grube E
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E163-72. PubMed ID: 23225766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial.
    Dangas GD; Claessen BE; Mehran R; Xu K; Stone GW
    EuroIntervention; 2013 Jan; 8(9):1033-9. PubMed ID: 23339809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy over time of a short overall atherosclerosis management programme on the reduction of cardiovascular risk in patients after an acute coronary syndrome.
    Lafitte M; Pradeau V; Leroux L; Richeboeuf V; Tastet S; Boulon C; Paviot B; Bonnet J; Couffinhal T
    Arch Cardiovasc Dis; 2009 Jan; 102(1):51-8. PubMed ID: 19233109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
    J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of atherothrombosis and vascular response to primary percutaneous coronary intervention in women versus men with acute myocardial infarction: results of the OCTAVIA study.
    Guagliumi G; Capodanno D; Saia F; Musumeci G; Tarantini G; Garbo R; Tumminello G; Sirbu V; Coccato M; Fineschi M; Trani C; De Benedictis M; Limbruno U; De Luca L; Niccoli G; Bezerra H; Ladich E; Costa M; Biondi Zoccai G; Virmani R;
    JACC Cardiovasc Interv; 2014 Sep; 7(9):958-68. PubMed ID: 25129664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with recurrent coronary events among patients with cardiovascular disease.
    McConnell KJ; Olson KL; Delate T; Merenich JA;
    Pharmacotherapy; 2009 Aug; 29(8):906-13. PubMed ID: 19637943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates in antiplatelet agents used in cardiovascular diseases.
    Cheng JW
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):514-24. PubMed ID: 24213473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.